CEO.ca audience, we exhibit several items direct from The Calandra Report. Thom Calandra will be visiting CEO.ca regularly. His TCR audience is active and pays as much as $101 yearly for the twice-weekly TCR reports,

Each of the following items should serve an audience looking for a short fuse on a trade. Our CEO.ca audience is getting this first, along with an alert to TCR subscribers. [Note: Ceo.ca and TCR believe our combined reach will benefit investors.]

-- BioCryst Pharmaceuticals (BCRX on Nasdaq in USA) looks to benefit from influenza outbreaks in North America. The drug developer from the Carolinas also is getting recognition for new drug apps that include gout, angio-edema, leukemia and recently, Marburg virus, which can cause hemorrhagic fever.

Stock chart technicians say the shares at $8.40 are at their highest point since early 2009, when a virulent H1N1 virus posed and partly delivered on the threat of worldwide sickness and death. Chartists look for an approximate $9.80 price within days or hours of hovering in the $8.50 range. The stock gaps up quickly. I own about 17,000 shares.

-- Taking SIPs: A Toronto technology developer, Wi2Wi Corp. (YTY in Canada and ISEYF in USA), is seeing an order backlog that might boost sales, and potential profit, in the recent booked quarter. YTY makes WiFi, WiFi-Bluetooth and GPS system-in-a-package (SiPs) for cars, trucks, medical and industrial applications. I paid 22 cents USA less than a week ago.

-- Order backlogs -- this time in a service company, if that's possible  -- almost surely will boost Sysorex Global Holdings (SYRX on USA bulletin board), a California-based computer systems integrator. I know the principals, who are attempting to combine several successful companies and then service government agencies and corporations.

The stock is difficult to purchase. I am confident the next sales report will show potent sequential and year-on-year sales growth. Comparable price-to-sales ratios for competitors in systems integrators are leagues above what SYRX trades for now. I started purchasing shares at $2. The stock is about $2.75. Executives are out trying to raise cash for more acquisitions,

-- Our TCR audience benefited from Inovio Pharmaceuticals (INO in New York) shares. INO shares are up $1 in five weeks to $2.85. The stock lost ground Friday to $2.65. Inovio is developing cancer and other vaccines and treatments using artificial DNA. Sister company OncoSec Medical (ONCS in USA) has seen its shares rise to 55 cents from about 26 cents in the same span.

Those who believe Inovio's DNA delivery method, electroporation, will prove successful in continuing human trials might look at INO as a six-month investment. Fresh data on one human trial will come by mid-2014. I own INO shares.

As for resources: Our fresh calendar year, 2014, brings a $36 rise in the gold price in two days. Metals equities in USA, Canada and elsewhere are rising -- mostly on gaps between bids and asks. The destruction of metals equities is closing out its third year; the slide began March 2011. My preferred poison the past 10 months, aside from 30 individual miners and prospectors, is the triple-charged NUGT, a derivative ETF. NUGT (in USA trading) is up about $6 in two days to $31. When NUGT returns to $50 or so, the trade will be even-Steven.

Until then, I continue to hold -- along with our TCR audience of 400 or so subscribers -- each of the TCR 8 preferred investments, all in resources. One of them, Pilot Gold (PLG in Canada), looks to advance its Nevada gold and silver project.

Your friendly,

Thom Calandra

THE CALANDRA REPORT: Subscribe

Thom Calandra

the calandra